Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates

Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists

(2017) Andreas Evers et al.   JOURNAL OF MEDICINAL CHEMISTRY

The New Biology and Pharmacology of Glucagon

(2017) T. D. Müller et al.   PHYSIOLOGICAL REVIEWS

Unimolecular Polypharmacy for Treatment of Diabetes and Obesity

(2016) Matthias H. Tschöp et al.   Cell Metabolism

Effects of 13-Hour Hyperglucagonemia on Energy Expenditure and Hepatic Glucose Production in Humans

(2016) Manu Chakravarthy et al.   DIABETES

Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates

(2016) S. J. Henderson et al.   DIABETES OBESITY & METABOLISM

Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice

(2016) F. P. M. O'Harte et al.   DIABETES OBESITY & METABOLISM

Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice

(2016) F.P.M. O'Harte et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Glucagon increases energy expenditure independently of brown adipose tissue activation in humans

(2015) V. Salem et al.   DIABETES OBESITY & METABOLISM

Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure

(2015) Jonatan Ising Bagger et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake

(2014) Jaimini Cegla et al.   DIABETES

A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation

(2014) Aisling M. Lynch et al.   DIABETOLOGIA

Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions

(2013) K. M. Habegger et al.   DIABETES

Role of Reduced  -Cell Mass Versus Impaired  -Cell Function in the Pathogenesis of Type 2 Diabetes

(2013) J. J. Meier et al.   DIABETES CARE

A Novel Glucagon-like Peptide-1 (GLP-1)/Glucagon Hybrid Peptide with Triple-acting Agonist Activity at Glucose-dependent Insulinotropic Polypeptide, GLP-1, and Glucagon Receptors and Therapeutic Potential in High Fat-fed Mice

(2013) Victor A. Gault et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Hypothalamic glucagon signaling inhibits hepatic glucose production

(2013) Patricia I Mighiu et al.   NATURE MEDICINE

Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents

(2012) Jonathan W. Day et al.   BIOPOLYMERS

Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia

(2012) T. M. Tan et al.   DIABETES

Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis?

(2012) A. M. Arafat et al.   DIABETOLOGIA

Minireview: Glucagon in Stress and Energy Homeostasis

(2012) B. J. Jones et al.   ENDOCRINOLOGY

Unraveling oxyntomodulin, GLP1's enigmatic brother

(2012) Alessandro Pocai   JOURNAL OF ENDOCRINOLOGY

The Glucagon Receptor Is Involved in Mediating the Body Weight-Lowering Effects of Oxyntomodulin

(2012) Jennifer R. Kosinski et al.   Obesity

DPP-IV-resistant, long-acting oxyntomodulin derivatives

(2011) Alessia Santoprete et al.   JOURNAL OF PEPTIDE SCIENCE

(d-Ser2)Oxm[mPEG-PAL]: A novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions

(2010) Barry D. Kerr et al.   BIOCHEMICAL PHARMACOLOGY

Liraglutide

(2010) Daniel J. Drucker et al.   NATURE REVIEWS DRUG DISCOVERY

Glucagon regulation of energy metabolism

(2010) Kristy M. Heppner et al.   PHYSIOLOGY & BEHAVIOR

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

(2009) A. Pocai et al.   DIABETES

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

(2009) Jonathan W Day et al.   Nature Chemical Biology

Increased Energy Expenditure Contributes More to the Body Weight-Reducing Effect of Rimonabant than Reduced Food Intake in Candy-Fed Wistar Rats

(2008) Andreas W. Herling et al.   ENDOCRINOLOGY

Physiology of the pancreatic α-cell and glucagon secretion: role in glucose homeostasis and diabetes

(2008) Ivan Quesada et al.   JOURNAL OF ENDOCRINOLOGY